Present: Drs. Wetmur, Miller, Pullium, Simon, TenOever and Wieder; Mr. Hauck; Mss. Meseck and Sadock.

Present via teleconference: Ms. Erlitz and Dr. Wieder.

1) Introduction of New Members
   a. The Committee welcomed new members, David Bishop, PhD, Benjamin TenOever, PhD and Marcia Meseck, MS, JD.

2) Approval of Minutes
   a. Upon motion duly made and seconded, the minutes of the November 20, 2008 meeting were unanimously approved.

3) BSL-3 Authorizations
   a. The Committee reviewed the projects currently approved for study in the EPF [see handout].
   b. There have been no protocol changes since the last approval.
   c. After discussion and motion duly made and seconded, current projects were re-approved for continuation through January 2010.
   d. SARS has not yet shipped.
      i. The SARS SOPs include recognition that the pathogen survives for days on the bench.
      ii. When new materials arrive, a decon challenge will be done to determine effectiveness.
      iii. Upon motion duly made and seconded, work with SARS was approved using the existing protocol.

4) BioVex Protocol [OncoVEX] (Kaufman, GCO#09-0245). [BioVex protocol #0810-947 entitled: A randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of a Treatment with OncoVEX Compared to Subcutaneously Administered GM-CSF in Previously Treated Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease.]
   a. Mr. Hauck outlined the risks of this protocol, noting that HSV positive people should be at no added risk. HSV negative people could react differently. There is no risk of recombination; no wild virus can emerge.
      i. The virus can replicate ad lib and affect people handling patients, who must employ standard isolation procedures (gloves and masks); HSV is not airborne transmissible.
      ii. Handling on the bench should be done with standard BSL 2 precautions, including Biosafety cabinet.
      iii. Upon motion duly made and seconded, this project was approved for handling at BSL2.